Zynteglo (betibeglogene autotemcel) for transfusion-dependent beta-thalassemia
Customize your policy alerts
Sign up for all CareSource policy alerts
Know when CareSource releases new policies or updates existing guidance.
Monitor payer policy activity
CareSource Arkansas PASSE medical prior authorization coverage for Zynteglo, a one-time gene therapy for eligible adult and pediatric members with beta-thalassemia; continued therapy is not authorized.
The policy added a requirement for genetic confirmation of the beta-thalassemia diagnosis.
The policy references were updated on March 2, 2026.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.